Showcasing Human Tissue Regenerative Medicine Solutions to Advance Clinical Applications in Musculoskeletal Repair

Issued by: ECM Biomedical – Marketing & Public Relations Department

Taipei, Taiwan — ECM Biomedical recently participated in the 2026 Sports Medicine Exhibition, showcasing its latest innovations in human tissue regenerative medicine. The Company highlighted its three core product platforms—Amniotic Matrix, Acellular Dermal Matrix (ADM), and Human Bone Allografts—while engaging with physicians and healthcare professionals from orthopedics, sports medicine, rehabilitation medicine, neurosurgery, and related specialties to explore the expanding clinical applications of human tissue technologies in musculoskeletal repair and regenerative medicine.

As the global population ages and the prevalence of musculoskeletal disorders continues to rise, regenerative medicine has become an increasingly important focus in sports medicine. Human tissue-derived biomaterials, recognized for their excellent biocompatibility and naturally occurring extracellular matrix (ECM), are gaining broader clinical interest for applications including tendon and ligament repair, soft tissue reconstruction, and bone regeneration.

Advancing Human Tissue Innovation for Regenerative Medicine

Under the theme "Human Tissue Innovation for Regenerative Medicine," ECM Biomedical presented its comprehensive human tissue technology platform, featuring products based on amniotic matrix, acellular dermal matrix, and human bone allografts.

These products support a wide range of clinical specialties, including orthopedics, sports medicine, rehabilitation medicine, reconstructive surgery, neurosurgery, dentistry, and aesthetic medicine, demonstrating the growing potential of human tissue technologies in tissue repair, reconstruction, and regenerative medicine.

Strengthening Clinical Collaboration Through Scientific Exchange

Throughout the exhibition, ECM Biomedical engaged with physicians, researchers, healthcare institutions, and industry partners from across Taiwan to exchange insights on the latest research trends and clinical experiences involving human tissue biomaterials in musculoskeletal repair, sports injuries, and bone reconstruction.

The Company believes that close collaboration with frontline healthcare professionals not only enhances its understanding of evolving clinical needs but also supports continuous product optimization and innovation. These exchanges further strengthen the integration of human tissue technologies into clinical practice and contribute to the advancement of regenerative medicine for musculoskeletal disorders.

Building a Comprehensive Human Tissue Portfolio

ECM Biomedical continues to invest in human tissue preservation technologies, manufacturing innovation, and quality management systems. The Company has established three core regenerative medicine platforms encompassing Amniotic Matrix, Acellular Dermal Matrix (ADM), and Human Bone Allografts, while progressively expanding into additional human tissue categories, including skin, cartilage, fascia, and ligaments, to build a comprehensive Human Tissue Portfolio.

Operating in accordance with Taiwan Food and Drug Administration (TFDA) Human Tissue Bank regulations, ECM Biomedical has implemented internationally aligned manufacturing and quality management systems to ensure product safety, consistency, and full traceability, supporting the growing clinical needs of regenerative medicine.

Driving the Future of Human Tissue Regenerative Medicine

ECM Biomedical stated that participating in the Sports Medicine Exhibition represents more than an opportunity to showcase its technologies and products—it also serves as an important platform for fostering clinical collaboration, promoting interdisciplinary exchange, and advancing innovation in regenerative medicine.

Looking ahead, the Company will continue to strengthen its expertise in human tissue preservation, product development, and clinical applications while collaborating with hospitals, research institutions, and international partners to expand the use of human tissue technologies in sports medicine, musculoskeletal repair, and a broad range of medical specialties.

Guided by its brand mission, "Advancing Healing with the Gift of Humanity," ECM Biomedical remains committed to integrating research, manufacturing, quality management, and global collaboration to build a world-class human tissue regenerative medicine platform and strengthen its position as a leading regenerative medicine company in Asia with a growing international presence.